查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1808362

發炎性腸道疾病治療市場按治療類型、給藥途徑、製劑類型、用途、最終用戶、分銷管道和患者類型分類 - 2025-2030 年全球預測

Inflammatory Bowel Disease Treatment Market by Treatment Type, Route Of Administration, Formulation Type, Application, End-User, Distribution Channel, Patient Type - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

發炎性腸道疾病治療市場預計在 2024 年達到 200.1 億美元，在 2025 年成長至 209.5 億美元，複合年成長率為 4.83%，到 2030 年將達到 265.6 億美元。

主要市場統計數據
基準年2024年 200.1億美元
預計2025年 209.5億美元
預測年份 2030 265.6億美元
複合年成長率（%） 4.83%

全面介紹影響發炎性腸道疾病治療生態系統的新興動態和關鍵促進因素

發炎性腸道疾病涵蓋頻譜複雜的慢性胃腸道疾病，其特徵是發炎反覆發作、患者發病率高以及迫切需要更有效的治療方法。近年來，先進生物製藥、精準醫療方法和不斷擴展的真實世界數據的融合，改變了我們對疾病病理生理學和治療模式的理解。隨著臨床試驗擴大納入分子亞型和創新終點，從藥物開發商到醫療保健系統的相關人員正在重新調整其策略，以利用新的機會。

在發炎性腸道疾病不斷發展的領域中，變革性變化重新定義了研究、治療方法和患者結果

在標靶免疫學和再生醫學突破的推動下，發炎性腸道疾病領域正在經歷根本性變革時期。發炎性腸道疾病市場歷來以小分子藥物和皮質類固醇為主，如今正轉向更安全、更有效、生物目標，例如整合素受體拮抗劑和白細胞介素抑制劑。同時，基因治療載體、微生物組修飾劑和幹細胞移植等先進療法正進入後期研發階段，可望恢復黏膜完整性和免疫穩態，進而達到持久緩解。

評估 2025 年美國關稅對 IBD 治療創新和市場准入的累積影響

預計2025年美國關稅政策的調整將對發炎性腸道疾病治療的供應鏈和成本結構產生深遠影響。關鍵原料和原料藥的進口關稅上調，可能迫使製造商重新評估籌資策略或承擔額外成本，可能影響價格談判和報銷談判。因此，決策者應密切關注政策發展，並探索替代原料採購和本地製造合作夥伴關係，以降低成本上漲。

深度細分洞察揭示治療方式、給藥途徑、製劑類型、應用、最終用戶和患者群體

發炎性腸道疾病治療市場從多個角度進行分析，以發現重大機會和未滿足的需求。治療類型涵蓋基礎小分子藥物，例如氨基水楊酸鹽、皮質類固醇和免疫抑制劑，以及尖端生物製藥製劑，例如腫瘤壞死因子抑制劑、白細胞介素阻斷劑和整合素受體拮抗劑。先進的治療方法正變得越來越多樣化，包括旨在重置免疫調節的基因療法、旨在恢復腸道菌群平衡的微生物組調節藥物，以及專注於再生受損腸道組織的幹細胞療法。對於難治性病例，外科手術介入仍然至關重要，從複雜解剖挑戰的切除術到切除術和狹窄成形術。

區域洞察重點介紹美洲、歐洲、中東和非洲地區以及亞太地區 IBD 藥物的成長動力和病患可及性趨勢

不同地區的發炎性腸道疾病 (IBD) 治療受不同因素的影響。在美洲，強大的醫療基礎設施和完善的報銷框架正在促進新型療法的快速應用。病患權益團體和臨床網路進一步提高了人們對IBD的認知，並支持早期診斷和堅持長期治療方法。然而，新的挑戰包括支付方對生物製藥高成本的監督，以及需要透過全面的病患登記來證明其在現實世界中的價值。

策略性公司概況和競爭定位突顯發炎性腸道疾病治療領域的創新途徑和市場領導地位

領先的製藥和生物技術公司正在推行多元化策略，以鞏固其在發炎性腸道疾病領域的地位。現有企業正在透過新一代抗體構建體和生物相似藥開發項目增強其生技藥品產品組合，而新興創新企業則利用先進的治療平台，並攜手合作，共同開發基因治療候選藥物和基於微生物的干涉措施。大型公司與敏捷的生物技術公司之間的合作，利用雙方在製程開發和臨床營運方面的互補專業知識，加速後期臨床試驗。

可行的策略建議，以推動永續成長、改善患者治療效果並促進 IBD 主要相關人員之間的合作

產業領導者應優先投資針對潛在疾病機制的差異化治療方法，例如標靶特異性較高、療效持久的下一代生技藥品。同時，將數位健康解決方案納入臨床試驗方案和上市後監測，可以促進以患者為中心的參與，並產生真實世界證據以支持報銷談判。此外，促進多方相關利益者合作，包括與學術研究中心、病患權益組織和合約研究組織建立夥伴關係，可以加速轉化研究，並簡化與監管機構的互動。

結合多源資料收集、定性和定量分析以及嚴格檢驗過程的調查方法

該研究整合了多種資訊方法，將廣泛的二手資料審查與透過深入訪談行業高管、臨床醫生和付款人收集的一手資訊相結合。二手資料研究涵蓋同行評審出版物、監管備案文件、臨床試驗資料庫和行業白皮書，旨在對治療機制、競爭格局和市場准入動態建立基礎理解。一手數據研究則包括與跨區域意見領袖進行結構化討論，以深入了解臨床應用促進因素和患者管理挑戰的微妙觀點。

綜合結論總結了不斷發展的發炎性腸道疾病治療市場中相關人員的主要發現和未來前景

本執行摘要全面分析了影響發炎性腸道疾病治療市場的關鍵趨勢，涵蓋從新型治療層級和先進治療方法到預期關稅變化的策略影響。細分分析揭示了產品差異化的關鍵途徑，包括治療類型、給藥途徑、製劑形式和患者群體。區域洞察突顯了多樣化的成長動力，涵蓋美洲成熟的報銷格局，歐洲、中東和非洲 (EMEA) 的監管協調工作，以及亞太地區激增的需求。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章市場動態

  • 微創治療對於提高 IBD 患者的依從性越來越重要
  • 個人化醫療方法在發炎性腸道疾病治療的應用日益增多
  • 調節腸道菌叢作為 IBD 的新治療策略正受到關注
  • 擴大小分子藥物研發管線，為發炎性腸道疾病 (IBD) 提供替代療法
  • 標靶藥物輸送系統的進展提高了發炎性腸道疾病 (IBD) 治療的有效性
  • 整合數位健康技術，遠端監控 IBD 患者
  • 過渡到聯合治療以改善發炎性腸道疾病的療效
  • 認知度的提高和早期診斷推動了對創新 IBD 治療的需求
  • 監管部門的核准加速了下一代 IBD 藥物的上市
  • 生物製劑和生物相似藥的出現正在改變全球 IBD 治療方案

第6章 市場洞察

  • 波特五力分析
  • PESTEL分析

第7章 2025年美國關稅的累積影響

8. 發炎性腸道疾病治療市場（依治療類型）

  • 先進治療
    • 基因治療
    • 微生物組調變器
    • 幹細胞療法
  • 生物製藥
    • 整合素受體拮抗劑
    • 白細胞介素抑制劑
    • TNF抑制劑
  • 小分子藥物
    • 氨基水楊酸鹽
    • 皮質類固醇
    • 免疫抑制劑
  • 外科手術
    • 造口
    • 切除
    • 狹窄成形術

9. 發炎性腸道疾病治療市場（依給藥途徑）

  • 注射
    • 靜脈
    • 皮下
  • 口服
  • 直腸

10. 發炎性腸道疾病治療市場（依處方類型）

  • 液體製劑
    • 口服溶液
    • 暫停
  • 腸外製劑
  • 固態劑型
    • 咀嚼片
    • 緩釋片

第 11 章炎症性腸道疾病治療市場：按應用

  • 克隆氏症
  • 非典型結腸炎
  • 潰瘍性大腸炎

12. 發炎性腸道疾病治療市場（依最終使用者）

  • 診所
  • 居家照護環境
  • 醫院

13. 發炎性腸道疾病治療市場（依分銷管道）

  • 醫院藥房
  • 網路藥局
  • 零售藥局

14. 發炎性腸道疾病治療市場（依患者型態）

  • 成年人口
  • 老年人口
  • 兒科族群

15.美洲發炎性腸道疾病治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

16. 歐洲、中東和非洲發炎性腸道疾病治療市場

  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 阿拉伯聯合大公國
  • 沙烏地阿拉伯
  • 南非
  • 丹麥
  • 荷蘭
  • 卡達
  • 芬蘭
  • 瑞典
  • 奈及利亞
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波蘭
  • 瑞士

17. 亞太地區發炎性腸道疾病治療市場

  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • 印尼
  • 泰國
  • 菲律賓
  • 馬來西亞
  • 新加坡
  • 越南
  • 台灣

第18章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Abbott Laboratories
    • AbbVie Inc.
    • Abivax
    • Amgen Inc.
    • Bristol-Myers Squibb Company
    • Cipla Limited
    • Eli Lilly and Company
    • Entera Bio Ltd.
    • FutureGen Biopharmaceutical（Beijing）Co., Ltd.
    • GlaxoSmithKline PLC
    • Ironwood Pharmaceuticals, Inc.
    • Johnson & Johnson Services, Inc.
    • Merck & Co., Inc.
    • Morphic Therapeutic, Inc.
    • Nestle SA
    • OPKO Health, Inc.
    • Pfizer Inc.
    • Sanofi SA
    • Sun Pharma Limited
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Ltd.
    • TScan Therapeutics, Inc.
    • UCB SA
    • Viatris Inc.
    • Zealand Pharma A/S

第19章 研究人工智慧

第20章 研究統計

第21章 研究聯絡人

第22章 研究報導

第23章 附錄

Product Code: MRR-563BF1FCFF1E

The Inflammatory Bowel Disease Treatment Market was valued at USD 20.01 billion in 2024 and is projected to grow to USD 20.95 billion in 2025, with a CAGR of 4.83%, reaching USD 26.56 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 20.01 billion
Estimated Year [2025] USD 20.95 billion
Forecast Year [2030] USD 26.56 billion
CAGR (%) 4.83%

A Comprehensive Introduction to Emerging Dynamics and Critical Drivers Shaping the Inflammatory Bowel Disease Treatment Ecosystem

Inflammatory bowel disease encompasses a complex spectrum of chronic gastrointestinal disorders characterized by relapsing inflammation, significant patient morbidity, and an urgent need for more effective therapies. In recent years, the convergence of advanced biologic agents, precision medicine approaches, and expanding real-world data has transformed our understanding of disease pathophysiology and treatment paradigms. As clinical trials increasingly embrace molecular subtyping and innovative endpoints, stakeholders from pharmaceutical developers to healthcare systems are realigning their strategies to capitalize on emerging opportunities.

Furthermore, dynamic shifts in patient demographics, regulatory frameworks, and reimbursement landscapes are elevating the demand for differentiated therapeutic solutions. Healthcare providers are seeking treatments that offer sustained remission with minimized safety concerns, while payers are scrutinizing value propositions to manage the economic burden of chronic immune-mediated diseases. As a result, industry participants are deploying multidisciplinary research and forging cross-sector collaborations to accelerate the development of pioneering modalities that aim to redefine standards of care in inflammatory bowel disease.

Transformational Shifts Redefining Research, Treatment Modalities, and Patient Outcomes in the Evolving Inflammatory Bowel Disease Landscape

The inflammatory bowel disease landscape has undergone fundamental transformations driven by breakthroughs in targeted immunology and regenerative medicine. Historically dominated by small molecule drugs and corticosteroids, the market has shifted toward precision-targeted biologics such as integrin receptor antagonists and interleukin inhibitors, which offer superior safety and efficacy profiles. Concurrently, advanced therapies-including gene therapy vectors, microbiome modulators, and stem cell transplantation-are entering late-stage development, promising durable remission through restoration of mucosal integrity and immune homeostasis.

Moreover, digital health innovations and remote monitoring tools are enabling real-time disease management and empowering patients to actively participate in therapy regimens. Advances in telemedicine platforms are streamlining follow-up care, reducing hospitalizations, and improving adherence. In parallel, evolving regulatory pathways now accommodate breakthrough designations and adaptive trial designs, expediting the translation of laboratory discoveries into clinical interventions. Together, these shifts are redefining competitive dynamics and creating fertile ground for next-generation therapies that target the root causes of inflammatory bowel disease.

Assessing the Projected Cumulative Impact of 2025 United States Tariffs on Therapeutic Innovation and Market Accessibility in IBD Care

Anticipated adjustments in United States tariff policies for 2025 carry far-reaching implications for the inflammatory bowel disease therapy supply chain and cost structures. Increased import duties on key raw materials and active pharmaceutical ingredients may compel manufacturers to reassess sourcing strategies or absorb additional expenses, potentially affecting pricing negotiations and reimbursement discussions. Consequently, decision makers must monitor policy developments closely and explore alternative materials procurement or localized production partnerships to mitigate cost escalations.

Furthermore, tariff-induced pressures could accelerate interest in domestic biomanufacturing capabilities, spurring investments in flexible facilities and contract development organizations to localize critical manufacturing processes. Such a shift would not only buffer companies against external trade fluctuations but also enhance supply chain resilience. At the same time, collaborations with regulatory bodies and industry coalitions will be essential to navigate potential compliance hurdles and secure timely approvals. By proactively addressing these tariff dynamics, stakeholders can safeguard market access and maintain momentum in bringing innovative IBD therapies to patients.

Deep Dive into Segmentation Insights Revealing Treatment Modalities, Administration Routes, Formulation Types, Applications, End-Users, and Patient Demographics

The inflammatory bowel disease treatment market is dissected across multiple dimensions to reveal critical opportunities and unmet needs. Based on treatment type, research efforts extend from foundational small molecule drugs such as aminosalicylates, corticosteroids, and immunosuppressants to cutting-edge biologic classes including tumor necrosis factor inhibitors, interleukin blockers, and integrin receptor antagonists. Advanced therapies further diversify the landscape through gene therapy constructs designed to reset immune regulation, microbiome modulators aiming to restore gut flora balance, and stem cell therapies focused on regenerating damaged intestinal tissue. Surgical interventions remain integral for refractory cases, with procedures ranging from ostomy creation to resections and strictureplasties tailored to complex anatomical challenges.

In addition, administration route segmentation highlights the strategic relevance of injectable formulations delivered intravenously or subcutaneously, complemented by patient-preferred oral and rectal therapies that foster adherence. Formulation type analysis underscores the distinction between liquid formulations, such as oral solutions and suspensions, versus solid dosage forms including chewable and extended release tablets, alongside specialized parenteral preparations. Treatment applications concentrate on Crohn's disease, indeterminate colitis, and ulcerative colitis, each presenting unique pathophysiology and therapeutic endpoints. Moreover, end-user settings span traditional hospital environments, specialized clinics, and increasingly vital home care scenarios that support self-administration. Distribution channels cut across hospital pharmacies, online platforms, and retail outlets to optimize patient access. Finally, patient type considerations differentiate adult, geriatric, and pediatric populations, ensuring that product development and care models address distinct safety, dosing, and compliance factors across life stages.

Regional Insights Unveiling Distinct Growth Drivers and Patient Access Dynamics across the Americas, EMEA, and Asia-Pacific in IBD Therapeutics

Regional dynamics shape the inflammatory bowel disease treatment landscape in distinct ways. In the Americas, robust healthcare infrastructure and established reimbursement frameworks facilitate rapid adoption of novel therapies. Patient advocacy groups and clinical networks further drive awareness, supporting early diagnosis and adherence to long-term treatment regimens. However, emerging challenges include payer scrutiny of high-cost biologics and the imperative to demonstrate real-world value through comprehensive patient registries.

In Europe, the Middle East, and Africa, a mosaic of regulatory environments influences market entry strategies. Harmonization efforts across the European Union streamline approval pathways, whereas variable reimbursement policies in the Middle East and Africa necessitate adaptive pricing models. Local manufacturing partnerships and public-private initiatives are increasingly critical to improve therapy availability and address regional disease burdens. Across Asia-Pacific, escalating IBD incidence, bolstered by lifestyle shifts and urbanization, is prompting governments to prioritize chronic disease management. Incentives for domestic biotech innovation and strategic licensing agreements are propelling new entrants into this high-growth arena, while generics and biosimilars play an essential role in expanding patient access.

Strategic Company Profiles and Competitive Positioning Highlighting Innovation Pathways and Market Leadership in Inflammatory Bowel Disease Treatment

Leading pharmaceutical and biotechnology companies are pursuing diverse strategies to secure their positions in the inflammatory bowel disease arena. Established players are enhancing their biologics portfolios with next-generation antibody constructs and biosimilar development programs. Meanwhile, emerging innovators are capitalizing on advanced therapy platforms, forging alliances to co-develop gene therapy candidates and microbiome-based interventions. Collaborative ventures between large-cap firms and nimble biotechs are accelerating late-stage trials, leveraging complementary expertise in process development and clinical operations.

Competitive positioning is also influenced by robust intellectual property protection and strategic patent litigation, as companies seek to extend exclusivity periods for high-value assets. In parallel, royalty monetization agreements and divestitures of non-core assets are optimizing balance sheets, enabling reinvestment in high-potential pipelines. As regulatory agencies exhibit greater flexibility through accelerated pathways and conditional approvals, organizations equipped with adaptive clinical trial designs and real-world evidence capabilities will gain a decisive advantage. Overall, the interplay of M&A activity, co-development partnerships, and innovation-driven collaboration is reshaping the competitive terrain.

Actionable Strategic Recommendations to Drive Sustainable Growth, Enhance Patient Outcomes, and Foster Collaboration among Key Stakeholders in IBD

Industry leaders should prioritize investment in differentiated modalities that address underlying disease mechanisms, such as next-generation biologics with enhanced targeting specificity and durable response profiles. In parallel, integrating digital health solutions into clinical trial protocols and post-market surveillance can foster patient-centric engagement and generate real-world evidence to support reimbursement negotiations. Furthermore, cultivating multi-stakeholder collaborations-including alliances with academic research centers, patient advocacy groups, and contract development organizations-will accelerate translational research and streamline regulatory interactions.

Moreover, supply chain resilience should be fortified by diversifying manufacturing footprints and exploring regional production partnerships to mitigate tariff impacts and logistical disruptions. Organizations are encouraged to adopt modular facility designs and flexible contract manufacturing strategies to adapt to evolving demand patterns. Lastly, a concerted focus on emerging markets-supported by localized value demonstration and tiered pricing frameworks-will unlock high-growth opportunities while advancing equitable access to transformative therapies.

Robust Research Methodology Combining Multi-Source Data Collection, Qualitative and Quantitative Analyses, and Rigorous Validation Processes

This research integrates a multi-source approach, combining extensive secondary data review with primary insights gathered through in-depth interviews with industry executives, clinicians, and payers. Secondary research encompassed peer-reviewed publications, regulatory filings, clinical trial databases, and industry white papers to establish a robust foundational understanding of therapeutic mechanisms, competitive landscapes, and market access dynamics. Primary engagements involved structured discussions with opinion leaders across geographies, uncovering nuanced perspectives on clinical adoption drivers and patient management challenges.

Quantitative analysis was conducted using proprietary data models that triangulate findings across independent datasets, ensuring rigorous validation of thematic conclusions. Qualitative thematic coding was applied to interview transcripts to identify recurring trends, unmet clinical needs, and strategic imperatives. Iterative validation workshops with domain experts further refined key insights and resolved information gaps. Together, these methodologies provide a comprehensive, reliable, and actionable framework for stakeholders navigating the inflammatory bowel disease treatment arena.

Comprehensive Conclusion Synthesizing Key Findings and Future Outlook for Stakeholders in the Evolving Inflammatory Bowel Disease Treatment Market

This executive summary has synthesized pivotal developments shaping the inflammatory bowel disease treatment market, from emerging therapeutic classes and advanced modalities to the strategic implications of anticipated tariff changes. Segmentation analysis has illuminated critical pathways for product differentiation across treatment types, administration routes, formulation formats, and patient demographics. Regional insights underscore the multiplicity of growth drivers-from mature reimbursement landscapes in the Americas to regulatory harmonization efforts in EMEA and surging demand trajectories in Asia-Pacific.

Competitive intelligence reveals that innovation convergence, strategic partnerships, and agile manufacturing approaches will determine market leadership moving forward. Actionable recommendations emphasize the importance of targeted investment in next-generation therapies, digital health integration, supply chain resilience, and market-specific access strategies. As stakeholders chart their strategies for 2025 and beyond, a proactive, evidence-based approach will be essential to unlocking value, enhancing patient outcomes, and sustaining long-term growth in this dynamic and high-stakes therapeutic domain.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Growing emphasis on minimally invasive therapies for better patient compliance in IBD
  • 5.2. Rising adoption of personalized medicine approaches in managing inflammatory bowel disease
  • 5.3. Increased focus on gut microbiome modulation as a novel IBD therapeutic strategy
  • 5.4. Expanding pipeline of small molecule drugs offering alternative treatments for IBD
  • 5.5. Advancements in targeted drug delivery systems improving efficacy in IBD therapies
  • 5.6. Integration of digital health technologies for remote monitoring of IBD patients
  • 5.7. Shift towards combination therapies to enhance treatment outcomes in inflammatory bowel disease
  • 5.8. Surge in awareness and early diagnosis driving demand for innovative IBD treatments
  • 5.9. Impact of regulatory approvals accelerating launch of next-generation IBD therapies
  • 5.10. Emergence of biologics and biosimilars transforming IBD treatment options globally

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Inflammatory Bowel Disease Treatment Market, by Treatment Type

  • 8.1. Introduction
  • 8.2. Advanced Therapies
    • 8.2.1. Gene Therapy
    • 8.2.2. Microbiome Modulators
    • 8.2.3. Stem Cell Therapy
  • 8.3. Biologics
    • 8.3.1. Integrin Receptor Antagonists
    • 8.3.2. Interleukin Inhibitors
    • 8.3.3. TNF Inhibitors
  • 8.4. Small Molecule Drugs
    • 8.4.1. Aminosalicylates
    • 8.4.2. Corticosteroids
    • 8.4.3. Immunosuppressants
  • 8.5. Surgical Procedures
    • 8.5.1. Ostomy
    • 8.5.2. Resection
    • 8.5.3. Strictureplasty

9. Inflammatory Bowel Disease Treatment Market, by Route Of Administration

  • 9.1. Introduction
  • 9.2. Injectable
    • 9.2.1. Intravenous
    • 9.2.2. Subcutaneous
  • 9.3. Oral
  • 9.4. Rectal

10. Inflammatory Bowel Disease Treatment Market, by Formulation Type

  • 10.1. Introduction
  • 10.2. Liquid Formulations
    • 10.2.1. Oral Solutions
    • 10.2.2. Suspensions
  • 10.3. Parenteral Preparations
  • 10.4. Solid Dosage Forms
    • 10.4.1. Chewable Tablets
    • 10.4.2. Extended Release Tablets

11. Inflammatory Bowel Disease Treatment Market, by Application

  • 11.1. Introduction
  • 11.2. Crohns Disease
  • 11.3. Indeterminate Colitis
  • 11.4. Ulcerative Colitis

12. Inflammatory Bowel Disease Treatment Market, by End-User

  • 12.1. Introduction
  • 12.2. Clinics
  • 12.3. Home Care Settings
  • 12.4. Hospitals

13. Inflammatory Bowel Disease Treatment Market, by Distribution Channel

  • 13.1. Introduction
  • 13.2. Hospital Pharmacies
  • 13.3. Online Pharmacies
  • 13.4. Retail Pharmacies

14. Inflammatory Bowel Disease Treatment Market, by Patient Type

  • 14.1. Introduction
  • 14.2. Adult Population
  • 14.3. Geriatric Population
  • 14.4. Pediatric Population

15. Americas Inflammatory Bowel Disease Treatment Market

  • 15.1. Introduction
  • 15.2. United States
  • 15.3. Canada
  • 15.4. Mexico
  • 15.5. Brazil
  • 15.6. Argentina

16. Europe, Middle East & Africa Inflammatory Bowel Disease Treatment Market

  • 16.1. Introduction
  • 16.2. United Kingdom
  • 16.3. Germany
  • 16.4. France
  • 16.5. Russia
  • 16.6. Italy
  • 16.7. Spain
  • 16.8. United Arab Emirates
  • 16.9. Saudi Arabia
  • 16.10. South Africa
  • 16.11. Denmark
  • 16.12. Netherlands
  • 16.13. Qatar
  • 16.14. Finland
  • 16.15. Sweden
  • 16.16. Nigeria
  • 16.17. Egypt
  • 16.18. Turkey
  • 16.19. Israel
  • 16.20. Norway
  • 16.21. Poland
  • 16.22. Switzerland

17. Asia-Pacific Inflammatory Bowel Disease Treatment Market

  • 17.1. Introduction
  • 17.2. China
  • 17.3. India
  • 17.4. Japan
  • 17.5. Australia
  • 17.6. South Korea
  • 17.7. Indonesia
  • 17.8. Thailand
  • 17.9. Philippines
  • 17.10. Malaysia
  • 17.11. Singapore
  • 17.12. Vietnam
  • 17.13. Taiwan

18. Competitive Landscape

  • 18.1. Market Share Analysis, 2024
  • 18.2. FPNV Positioning Matrix, 2024
  • 18.3. Competitive Analysis
    • 18.3.1. Abbott Laboratories
    • 18.3.2. AbbVie Inc.
    • 18.3.3. Abivax
    • 18.3.4. Amgen Inc.
    • 18.3.5. Bristol-Myers Squibb Company
    • 18.3.6. Cipla Limited
    • 18.3.7. Eli Lilly and Company
    • 18.3.8. Entera Bio Ltd.
    • 18.3.9. FutureGen Biopharmaceutical (Beijing) Co., Ltd.
    • 18.3.10. GlaxoSmithKline PLC
    • 18.3.11. Ironwood Pharmaceuticals, Inc.
    • 18.3.12. Johnson & Johnson Services, Inc.
    • 18.3.13. Merck & Co., Inc.
    • 18.3.14. Morphic Therapeutic, Inc.
    • 18.3.15. Nestle S.A.
    • 18.3.16. OPKO Health, Inc.
    • 18.3.17. Pfizer Inc.
    • 18.3.18. Sanofi SA
    • 18.3.19. Sun Pharma Limited
    • 18.3.20. Takeda Pharmaceutical Company Limited
    • 18.3.21. Teva Pharmaceutical Industries Ltd.
    • 18.3.22. TScan Therapeutics, Inc.
    • 18.3.23. UCB S.A.
    • 18.3.24. Viatris Inc.
    • 18.3.25. Zealand Pharma A/S

19. ResearchAI

20. ResearchStatistics

21. ResearchContacts

22. ResearchArticles

23. Appendix

LIST OF FIGURES

  • FIGURE 1. INFLAMMATORY BOWEL DISEASE TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
  • FIGURE 16. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2024 VS 2030 (%)
  • FIGURE 18. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 20. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 22. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 25. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 26. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 27. INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. INFLAMMATORY BOWEL DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 29. INFLAMMATORY BOWEL DISEASE TREATMENT MARKET: RESEARCHAI
  • FIGURE 30. INFLAMMATORY BOWEL DISEASE TREATMENT MARKET: RESEARCHSTATISTICS
  • FIGURE 31. INFLAMMATORY BOWEL DISEASE TREATMENT MARKET: RESEARCHCONTACTS
  • FIGURE 32. INFLAMMATORY BOWEL DISEASE TREATMENT MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY MICROBIOME MODULATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY MICROBIOME MODULATORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INTEGRIN RECEPTOR ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INTEGRIN RECEPTOR ANTAGONISTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY AMINOSALICYLATES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY AMINOSALICYLATES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY OSTOMY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY OSTOMY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY RESECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY RESECTION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY STRICTUREPLASTY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY STRICTUREPLASTY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY RECTAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY RECTAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ORAL SOLUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ORAL SOLUTIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SUSPENSIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PARENTERAL PREPARATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PARENTERAL PREPARATIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY CHEWABLE TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY CHEWABLE TABLETS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY EXTENDED RELEASE TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY EXTENDED RELEASE TABLETS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 83. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2025-2030 (USD MILLION)
  • TABLE 85. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 87. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY CROHNS DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY CROHNS DISEASE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 89. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INDETERMINATE COLITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INDETERMINATE COLITIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 91. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 93. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 95. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 97. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 99. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 101. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 103. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 105. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 107. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 109. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 111. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADULT POPULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADULT POPULATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 113. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY GERIATRIC POPULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY GERIATRIC POPULATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 115. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PEDIATRIC POPULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PEDIATRIC POPULATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 117. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 118. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 119. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 120. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2025-2030 (USD MILLION)
  • TABLE 121. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 122. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
  • TABLE 123. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2024 (USD MILLION)
  • TABLE 124. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2025-2030 (USD MILLION)
  • TABLE 125. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2024 (USD MILLION)
  • TABLE 126. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2025-2030 (USD MILLION)
  • TABLE 127. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 128. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 129. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 130. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
  • TABLE 131. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 132. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2025-2030 (USD MILLION)
  • TABLE 133. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2024 (USD MILLION)
  • TABLE 134. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2025-2030 (USD MILLION)
  • TABLE 135. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2024 (USD MILLION)
  • TABLE 136. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2025-2030 (USD MILLION)
  • TABLE 137. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 138. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 139. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 140. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 141. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 142. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 143. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 145. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 147. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 148. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 149. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 150. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2025-2030 (USD MILLION)
  • TABLE 151. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 152. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
  • TABLE 153. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2024 (USD MILLION)
  • TABLE 154. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2025-2030 (USD MILLION)
  • TABLE 155. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2024 (USD MILLION)
  • TABLE 156. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2025-2030 (USD MILLION)
  • TABLE 157. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 158. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 159. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 160. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
  • TABLE 161. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 162. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2025-2030 (USD MILLION)
  • TABLE 163. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2024 (USD MILLION)
  • TABLE 164. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2025-2030 (USD MILLION)
  • TABLE 165. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2024 (USD MILLION)
  • TABLE 166. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2025-2030 (USD MILLION)
  • TABLE 167. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 168. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 169. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 170. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 171. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 172. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 173. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 175. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 176. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 177. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 178. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 179. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 180. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2025-2030 (USD MILLION)
  • TABLE 181. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 182. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
  • TABLE 183. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2024 (USD MILLION)
  • TABLE 184. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2025-2030 (USD MILLION)
  • TABLE 185. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2024 (USD MILLION)
  • TABLE 186. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2025-2030 (USD MILLION)
  • TABLE 187. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 188. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 189. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 190. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
  • TABLE 191. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2025-2030 (USD MILLION)
  • TABLE 193. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2024 (USD MILLION)
  • TABLE 194. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2025-2030 (USD MILLION)
  • TABLE 195. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2024 (USD MILLION)
  • TABLE 196. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2025-2030 (USD MILLION)
  • TABLE 197. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 198. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 199. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 200. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 201. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 202. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 203. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 205. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 207. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 208. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2025-2030 (USD MILLION)
  • TABLE 209. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 210. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
  • TABLE 211. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2024 (USD MILLION)
  • TABLE 212. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2025-2030 (USD MILLION)
  • TABLE 213. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2024 (USD MILLION)
  • TABLE 214. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2025-2030 (USD MILLION)
  • TABLE 215. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 216. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 217. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 218. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
  • TABLE 219. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2025-2030 (USD MILLION)
  • TABLE 221. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2024 (USD MILLION)
  • TABLE 222. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2025-2030 (USD MILLION)
  • TABLE 223. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2024 (USD MILLION)
  • TABLE 224. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2025-2030 (USD MILLION)
  • TABLE 225. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 226. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 227. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 228. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 229. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 230. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 231. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 233. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 235. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 236. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2025-2030 (USD MILLION)
  • TABLE 237. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 238. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
  • TABLE 239. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2024 (USD MILLION)
  • TABLE 240. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2025-2030 (USD MILLION)
  • TABLE 241. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2024 (USD MILLION)
  • TABLE 242. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2025-2030 (USD MILLION)
  • TABLE 243. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 244. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 245. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 246. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
  • TABLE 247. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2025-2030 (USD MILLION)
  • TABLE 249. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2024 (USD MILLION)
  • TABLE 250. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2025-2030 (USD MILLION)
  • TABLE 251. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2024 (USD MILLION)
  • TABLE 252. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2025-2030 (USD MILLION)
  • TABLE 253. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 254. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 255. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 256. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 257. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 258. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 259. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 261. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 263. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 264. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2025-2030 (USD MILLION)
  • TABLE 265. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 266. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
  • TABLE 267. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2024 (USD MILLION)
  • TABLE 268. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2025-2030 (USD MILLION)
  • TABLE 269. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2024 (USD MILLION)
  • TABLE 270. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2025-2030 (USD MILLION)
  • TABLE 271. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 272. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 273. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 274. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
  • TABLE 275. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2025-2030 (USD MILLION)
  • TABLE 277. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2024 (USD MILLION)
  • TABLE 278. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2025-2030 (USD MILLION)
  • TABLE 279. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2024 (USD MILLION)
  • TABLE 280. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2025-2030 (USD MILLION)
  • TABLE 281. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 282. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 283. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)

TABLE 2